Latest news with #NEUROMARK
Yahoo
30-06-2025
- Health
- Yahoo
Neurent Medical Announces Expanded Access Following Cigna Policy Update for NEUROMARK®
Effective September 15, CPT 31242 is no longer considered experimental, clearing an important barrier for ENT physicians treating chronic rhinitis. GALWAY, Ireland, June 30, 2025 /PRNewswire/ -- Neurent Medical, a leader in non-surgical treatments for chronic rhinitis, today announced that Cigna Healthcare will provide coverage for NEUROMARK treatment of the posterior nasal nerve by removing CPT 31242 posterior nasal nerve ablation using radiofrequency from its Experimental & Investigational (E&I) list, effective September 15th, 2025. This policy update is an important step in improving patient access to innovative treatment options for chronic rhinitis and reflects growing payer recognition of the procedure's therapeutic value. This update removes a key barrier that previously limited the ability for ENT physicians to treat Cigna patients using posterior nasal nerve ablation. "This is a significant moment for ENT providers and patients alike," said Brian Shields, CEO of Neurent Medical. "Cigna's reclassification of CPT 31242 reinforces the evolving understanding of chronic rhinitis and the role of targeted, minimally invasive interventions like NEUROMARK in managing the condition. We are committed to continue building on our large evidence base and working closely with the American Academy of Otolaryngology-Head and Neck Surgery (AAO-HNS) to support adoption across the US healthcare system" The NEUROMARK System delivers impedance-controlled, low-power radiofrequency (RF) energy to disrupt the parasympathetic nerve signals, addressing key symptoms of Chronic Rhinitis such as persistent nasal congestion and rhinorrhea (runny nose). "Chronic rhinitis can significantly affect an individual's wellbeing and patients need access to all available, medically sound solutions" said Dr. Peter Manes, Associate Professor at Yale School of Medicine. "This policy update is significant and helps otolaryngologists offer a modern, evidence-supported treatment with fewer administrative hurdles. The large and growing evidence base makes it more difficult for patients to be denied access to such technologies." Key Points for Providers: CPT 31242 is no longer classified as investigational by Cigna Precertification is not required under the updated policy (always confirm benefits per individual plan) The policy supports more streamlined access to NEUROMARK for eligible patients To view Cigna's updated medical policy, visit:CIGNA Policy LINK For more information about NEUROMARK, visit or contact your local Neurent Medical Sales Representative. About Neurent Medical Neurent Medical is pioneering innovative treatments for chronic inflammatory sinonasal diseases by targeting and safely disrupting hyperactive autonomic nerves that drive underlying inflammation. Its proprietary NEUROMARK® technology, with a unique design and advanced smart algorithmic control, allows physicians to precisely target and safely disrupt multiple underlying nerve branches in a single procedure to alleviate chronic rhinitis symptoms and improve patient quality of life. The venture capital-backed company is headquartered in Galway, Ireland, with US HQ in Braintree, MA. For more information visit PAM225r01 View original content to download multimedia: SOURCE Neurent Medical
Irish Examiner
17-06-2025
- Business
- Irish Examiner
Medtech firm Neurent to create 125 jobs in Galway hub
Healthcare company Neurent Medical is to create 125 jobs in Galway at its new manufacturing facility at Westlink Commercial Park in Oranmore. The company is a leader in ear, nose, and throat (ENT) healthcare solutions and will create positions in engineering, quality control, operations, supply chain, and sales and marketing at the new facility, over the next three years. The Galway headquarters will serve as a hub for production of the company's Neuromark treatment option to treat chronic rhinitis. 'We're proud to scale our operations in Galway, where the medtech ecosystem continues to thrive. Our new Westlink facility gives us the manufacturing capacity to meet growing demand for Neuromark, while creating high skilled employment opportunities and contributing to economic vitality in the west of Ireland," said Neurent Medical chief Brian Shields. Neurent's Neuromark system recently received US FDA 510(k) clearance, which paves the way for broader commercialisation of its product in the US. "Neurent Medical has experienced impressive growth in a short period of time beginning its journey through the BioInnovate Ireland Programme here in Galway with further support awarded through EI's Commercialisation fund programme and through the Disruptive Technologies Innovation Fund administered by Enterprise Ireland for the development of the NEUROMARK technology,' said incoming Enterprise Ireland chief Jenny Melia.
Yahoo
12-06-2025
- Health
- Yahoo
FDA clears Neurent Medical's NEUROMARK for chronic rhinitis treatment
The US Food and Drug Administration (FDA) has granted 510(k) clearance to Neurent Medical's NEUROMARK system for the treatment of individuals with chronic rhinitis. Comprising a single-use, handheld bipolar radiofrequency (RF) device and a reusable console with a graphical user interface, the system is designed to conform to the anatomy of the patient and target nerve-rich regions in the nasal cavity. Its bioimpedance monitoring technology adjusts energy delivery based on the changes in tissue conductivity. This method makes sure treatment is precise by continuously evaluating the conditions of the tissue and adjusting energy flow, thereby increasing therapeutic outcomes. According to the company, the system's real-time feedback and smart algorithmic control are crucial for directing the proper placement of the electrode and ensuring treatment delivery success. Its atraumatic leaflets and flexible haft will aid physicians in accessing challenging nasal cavity areas and increase the treatment coverage, along with the posterior areas of the lateral nasal wall. The system claims to operate by delivering impedance-controlled, low-power RF energy to disrupt parasympathetic nerve signals. This addresses the primary symptoms of chronic rhinitis, which include rhinorrhoea (runny nose) and persistent congestion in the nasal area. With the FDA clearance, the system is set for broader availability in the US market. The Ireland-based company focuses on chronic inflammatory sino-nasal disease treatments. Neurent Medical CEO Brian Shields said: 'We have just completed a highly successful commercial validation phase, positioning the NEUROMARK system at the forefront of chronic rhinitis care. 'During this phase, we collaborated with leading General ENT [ear, nose, and throat] and rhinology specialists across both private practice and academic settings. Their insights were instrumental in shaping this next-generation system. I am incredibly proud of how their feedback translated into meaningful technological improvements.' "FDA clears Neurent Medical's NEUROMARK for chronic rhinitis treatment" was originally created and published by Medical Device Network, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
